AI Visibility Scorecard
Compassionate Use Programs: Expanded Access to Investigational Drugs
amplyx.com · Healthcare
Borderline visible. AI bots can crawl Compassionate Use Programs: Expanded Access to Investigational Drugs, but the structured-data signals are thin - you are at real risk of being skipped when buyers ask ChatGPT, Claude, or Perplexity for a recommendation.
AI engines read this profile 5 times
Apple Intelligence · Meta AI · Claude
#46,655 of 924,334 in Healthcare for AI visibility
<1
4
AEO Visibility
iBorderline · 4.2/10
30
Muse Index Score
iAI agent readiness
Agent-ready · 30/100
8
AI Adoption
iBasic · 8/100
About Compassionate Use Programs: Expanded Access to Investigational Drugs
from our crawl and measurement
Compassionate Use Programs: Expanded Access to Investigational Drugs describes itself simply: "How patients facing serious illnesses can learn more about requesting pre-approval access to investigational drugs." When AI engines look at it, they find little to work with. It scores 4.2 out of 10.
Under the hood there is structured data on the page (Organization, WebSite) and substantial page content, but the score is capped by what is missing: an llms.txt file, a sitemap, a heading structure that lays out what it offers.
The 6 signals AI reads
Strong · Good · Fair · Weak
Structured Data
Good
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
Strong
Clear headings and answer-style content.
Entity Clarity
Good
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
Strong
Experience, Expertise, Authority, Trust markers.
Technical AEO
Good
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
Strong
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
Weak
No inbound links found yet.
Domain Authority
Weak
Little domain authority yet.
Reference Presence
Weak
Not in AI knowledge graphs yet.
News & Press
Weak
No press coverage found yet.
Community
Weak
No community discussion yet.
Social Mentions
Weak
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 4.2/10, Compassionate Use Programs: Expanded Access to Investigational Drugs is crawlable but under-signaled - fixable, and the signals above are where to start.
Is this your brand?
The exact fixes for Compassionate Use Programs: Expanded Access to Investigational Drugs
Which AI engines already crawl you
Free AI bot monitoring: see every AI crawler that visits you
Already have an account? Sign in
How to Get Your Brand Cited by ChatGPT, Gemini, and Claude: The Complete AEO Guide
The search landscape has fundamentally shifted. While Google still dominates, millions of users now ask questions to ChatGPT, Gemini, and Claude instead of typing into a search bar.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Compassionate Use Programs: Expanded Access to Investigational Drugs.
Source & Attribution
Scored by Engagemii on July 31, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/amplyx
Cite this score: Engagemii (2026). "AEO Score for Compassionate Use Programs: Expanded Access to Investigational Drugs." Retrieved from https://engagemii.com/aeo/brands/amplyx
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform